DiaMedica appoints Tanya Lewis to board; Burroughs resigns

DiaMedica Therapeutics Inc.

Amy L. Burroughs resigned as director effective March 1, 2023; no disagreement with company.
Tanya N. Lewis appointed to fill vacancy, effective March 1, 2023.
Lewis is Chief Development Operations Officer at Replimune (Nasdaq:REPL) with 25+ years drug development experience.
Lewis received option to purchase 26,443 shares at $1.77/share, vesting quarterly over 3 years.
Company working to resolve clinical hold on ReMEDy2 AIS trial.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tanya N. Lewis

director

DMAC · DiaMedica Therapeutics Inc.

Effective: 2023-03-01
Filed: March 6, 2023, 6:59 PM ET

To fill the vacancy created by Ms. Burroughs’s resignation, on March 1, 2023, the Company’s Board of Directors (the “Board”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Tanya N. Lewis to the Board, effective immediately, to fill the vacancy created by Ms. Burroughs’s resignation.

Departed

Amy L. Burroughs

director

DMAC · DiaMedica Therapeutics Inc.

Effective: 2023-03-01
Successor: Tanya N. Lewis
Filed: March 6, 2023, 6:59 PM ET

On March 1, 2023, Amy L. Burroughs resigned as a director of DiaMedica Therapeutics Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tanya N. Lewis was appointed as director at DiaMedica Therapeutics Inc..

Action: appointed
Role: director

Exact text from the filing

To fill the vacancy created by Ms. Burroughs’s resignation, on March 1, 2023, the Company’s Board of Directors (the “Board”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Tanya N. Lewis to the Board, effective immediately, to fill the vacancy created by Ms. Burroughs’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy L. Burroughs resigned as director at DiaMedica Therapeutics Inc..

Action: resigned
Role: director

Exact text from the filing

On March 1, 2023, Amy L. Burroughs resigned as a director of DiaMedica Therapeutics Inc.

View on SEC.gov

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-005471

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.